BR112013005195A2 - forma de dosagem resistente à violação compreendendo um polímero aniônico - Google Patents
forma de dosagem resistente à violação compreendendo um polímero aniônicoInfo
- Publication number
- BR112013005195A2 BR112013005195A2 BR112013005195A BR112013005195A BR112013005195A2 BR 112013005195 A2 BR112013005195 A2 BR 112013005195A2 BR 112013005195 A BR112013005195 A BR 112013005195A BR 112013005195 A BR112013005195 A BR 112013005195A BR 112013005195 A2 BR112013005195 A2 BR 112013005195A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- tamper resistant
- anionic
- anionic polymer
- polysaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
forma de dosagem resistente à violação compreendendo um polímero aniônico. a presente invenção refere-se a uma forma de dosagem farmacêutica que exibe uma resistência à ruptura de pelo menos 500 n, a referida forma de dosagem contendo: - um ingrediente farmacologicamente ativo(a); - um polissacarídeo aniônico (b) obtenível por meio de introdução de grupos funcionais aniônicos, na forma protonada, ou um sal fisiologicamente aceitável do mesmo, em um polissacarídeo; e - um óxido de polialquileno (c); em que o ingrediente farmacologicamente ativo (a) está presente em uma matriz com liberação controlada compreendendo o polissacarídeo aniônico (b) e o óxido de polialquileno (c).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10009124 | 2010-09-02 | ||
PCT/EP2011/004404 WO2012028317A1 (en) | 2010-09-02 | 2011-09-01 | Tamper resistant dosage form comprising an anionic polymer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013005195A2 true BR112013005195A2 (pt) | 2016-07-12 |
Family
ID=43897069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013005195A BR112013005195A2 (pt) | 2010-09-02 | 2011-09-01 | forma de dosagem resistente à violação compreendendo um polímero aniônico |
Country Status (22)
Country | Link |
---|---|
US (1) | US20120059065A1 (pt) |
EP (1) | EP2611428B1 (pt) |
JP (1) | JP5925778B2 (pt) |
KR (1) | KR20130097201A (pt) |
CN (2) | CN103179956A (pt) |
AR (1) | AR082861A1 (pt) |
AU (1) | AU2011297954B2 (pt) |
BR (1) | BR112013005195A2 (pt) |
CA (1) | CA2808988C (pt) |
CL (1) | CL2013000423A1 (pt) |
CO (1) | CO6670598A2 (pt) |
EC (1) | ECSP13012473A (pt) |
ES (1) | ES2534847T3 (pt) |
HK (1) | HK1184389A1 (pt) |
IL (1) | IL224616A (pt) |
MX (1) | MX340427B (pt) |
NZ (1) | NZ607479A (pt) |
PE (1) | PE20131125A1 (pt) |
PL (1) | PL2611428T3 (pt) |
RU (1) | RU2013114411A (pt) |
TW (1) | TWI501788B (pt) |
WO (1) | WO2012028317A1 (pt) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
EP2301526B1 (en) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102005005446A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
ES2599031T3 (es) | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
PT2456424E (pt) * | 2009-07-22 | 2013-09-30 | Gruenenthal Gmbh | Forma de dosagem resistente à adulteração e estabilizada contra a oxidação |
NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
WO2011095314A2 (en) * | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
CA2808541C (en) | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
RS57913B1 (sr) | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
EA201590165A1 (ru) | 2012-07-06 | 2015-08-31 | Эгалет Лтд. | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения |
ES2698611T3 (es) | 2012-07-12 | 2019-02-05 | SpecGx LLC | Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
EP3285747A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
EP3285744A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
US11234974B2 (en) | 2015-05-28 | 2022-02-01 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
US10183018B2 (en) | 2015-05-28 | 2019-01-22 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3490537A1 (en) | 2016-08-01 | 2019-06-05 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US6471120B1 (en) * | 2001-10-25 | 2002-10-29 | Colgate Palmolive Company | Easy opening handled carton |
DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP2301526B1 (en) * | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US8075872B2 (en) * | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
PT1842533E (pt) * | 2003-08-06 | 2013-05-17 | Gruenenthal Gmbh | Forma de dosagem protegida contra abuso |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
EP1740156B8 (de) | 2004-04-22 | 2012-07-11 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
EP1765298B1 (de) | 2004-07-01 | 2012-10-24 | Gruenenthal Gmbh | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
CA2572491A1 (en) | 2004-07-01 | 2006-01-12 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse |
EP1786403B1 (de) | 2004-07-01 | 2013-07-24 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1991207A2 (en) * | 2006-01-21 | 2008-11-19 | Abbott GmbH & Co. KG | Dosage form and method for the delivery of drugs of abuse |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
KR100970665B1 (ko) * | 2008-02-04 | 2010-07-15 | 삼일제약주식회사 | 알푸조신 또는 그의 염을 함유하는 서방성 정제 |
EP2389169A1 (en) * | 2009-01-26 | 2011-11-30 | Egalet A/S | Controlled release formulations with continuous efficacy |
-
2011
- 2011-09-01 CN CN2011800420125A patent/CN103179956A/zh active Pending
- 2011-09-01 AR ARP110103191A patent/AR082861A1/es unknown
- 2011-09-01 BR BR112013005195A patent/BR112013005195A2/pt not_active IP Right Cessation
- 2011-09-01 MX MX2013002120A patent/MX340427B/es active IP Right Grant
- 2011-09-01 CN CN201710507176.XA patent/CN107308124A/zh active Pending
- 2011-09-01 PE PE2013000330A patent/PE20131125A1/es active IP Right Grant
- 2011-09-01 US US13/223,358 patent/US20120059065A1/en not_active Abandoned
- 2011-09-01 CA CA2808988A patent/CA2808988C/en not_active Expired - Fee Related
- 2011-09-01 KR KR1020137008511A patent/KR20130097201A/ko not_active Application Discontinuation
- 2011-09-01 NZ NZ607479A patent/NZ607479A/en not_active IP Right Cessation
- 2011-09-01 EP EP11761000.6A patent/EP2611428B1/en not_active Not-in-force
- 2011-09-01 JP JP2013526359A patent/JP5925778B2/ja not_active Expired - Fee Related
- 2011-09-01 ES ES11761000.6T patent/ES2534847T3/es active Active
- 2011-09-01 RU RU2013114411/15A patent/RU2013114411A/ru not_active Application Discontinuation
- 2011-09-01 PL PL11761000T patent/PL2611428T3/pl unknown
- 2011-09-01 WO PCT/EP2011/004404 patent/WO2012028317A1/en active Application Filing
- 2011-09-01 AU AU2011297954A patent/AU2011297954B2/en not_active Ceased
- 2011-09-01 TW TW100131418A patent/TWI501788B/zh not_active IP Right Cessation
-
2013
- 2013-02-07 IL IL224616A patent/IL224616A/en active IP Right Grant
- 2013-02-11 CO CO13027448A patent/CO6670598A2/es unknown
- 2013-02-12 CL CL2013000423A patent/CL2013000423A1/es unknown
- 2013-03-01 EC ECSP13012473 patent/ECSP13012473A/es unknown
- 2013-10-24 HK HK13111942.1A patent/HK1184389A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX340427B (es) | 2016-07-08 |
CL2013000423A1 (es) | 2013-04-12 |
KR20130097201A (ko) | 2013-09-02 |
ECSP13012473A (es) | 2013-04-30 |
US20120059065A1 (en) | 2012-03-08 |
NZ607479A (en) | 2015-06-26 |
CA2808988A1 (en) | 2012-03-08 |
AU2011297954B2 (en) | 2014-05-15 |
AR082861A1 (es) | 2013-01-16 |
AU2011297954A1 (en) | 2013-03-14 |
HK1184389A1 (en) | 2014-01-24 |
MX2013002120A (es) | 2013-04-03 |
CN107308124A (zh) | 2017-11-03 |
JP2013536809A (ja) | 2013-09-26 |
CN103179956A (zh) | 2013-06-26 |
TW201212954A (en) | 2012-04-01 |
IL224616A (en) | 2017-06-29 |
CO6670598A2 (es) | 2013-05-15 |
ES2534847T3 (es) | 2015-04-29 |
CA2808988C (en) | 2018-05-01 |
RU2013114411A (ru) | 2014-10-10 |
JP5925778B2 (ja) | 2016-05-25 |
EP2611428A1 (en) | 2013-07-10 |
WO2012028317A1 (en) | 2012-03-08 |
PE20131125A1 (es) | 2013-10-21 |
PL2611428T3 (pl) | 2015-06-30 |
EP2611428B1 (en) | 2015-01-14 |
TWI501788B (zh) | 2015-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013005195A2 (pt) | forma de dosagem resistente à violação compreendendo um polímero aniônico | |
BR112013005234A2 (pt) | forma de dosagem resistente à violação compreendendo um polímero aniônico. | |
ECSP13012474A (es) | Forma de dosificación resistente a manipulación que comprende una sal inorgánica | |
BR112015029616A2 (pt) | forma de dosagem resistente à adulteração com perfil de liberação bimodal | |
MX2010008138A (es) | Forma de dosis farmaceutica. | |
BR112015026549A2 (pt) | forma de dosagem à prova de violação contendo uma ou mais partículas | |
BR112014019988A8 (pt) | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico | |
BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
BR112017021475A2 (pt) | forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente | |
BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
UY30578A1 (es) | Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones | |
BRPI0814899A2 (pt) | Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo" | |
BR112015018168A2 (pt) | inibidores de rock suaves | |
BR112014022214A2 (pt) | fenólicos antibacterianos | |
BR112013002296A2 (pt) | composição farmacêutica e respectivo uso e método para tratar doença infecciosa | |
BR112013000189A2 (pt) | compostos de piridina anelados | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
ES2524385R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
BR112013029149A2 (pt) | processo de produção de material inorgânico em partículas | |
UY32650A (es) | Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas | |
BR112014004753A2 (pt) | formulação de liberação de multicamadas | |
BR112015006243A2 (pt) | agentes antibacterianos de fenicol | |
MX2010000120A (es) | Estereoisomeros de triciclodecan-9-il-xantogenato. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |